소아 간모세포종의 임상적 고찰

Purpose: By the help of neoadjuvant chemotherapy, resectability and survival rate of hepatoblastoma have improved. To evaluate recent treatment outcome of hepat-oblastoma, pediatric hepatoblastoma in our institute were reviewed. Methods: The medical records of 11 pediatric hepatoblastoma patients we...

Full description

Saved in:
Bibliographic Details
Published inAnnals of surgical treatment and research Vol. 63; no. 4; pp. 337 - 341
Main Authors 박진환(Jin Wan Park), 박재범(Jae Berm Park), 한상아(Sang Ah Han), 우종국(Jong Gook Woo), 서정민(Jeong Meen Seo), 이석구(Suk-Koo Lee)
Format Journal Article
LanguageKorean
Published 대한외과학회 01.10.2002
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose: By the help of neoadjuvant chemotherapy, resectability and survival rate of hepatoblastoma have improved. To evaluate recent treatment outcome of hepat-oblastoma, pediatric hepatoblastoma in our institute were reviewed. Methods: The medical records of 11 pediatric hepatoblastoma patients were analysed retrospectively. Results: All but one patient old were under 3 years old at diagnosis (range: 1~150 months). The male to female ratio was 6:5. Two patients were treated without neoadjuvant chemotherapy. One of them received right lobectomy for initially resectable tumor. Another one patient received a liver transplant for multiple unresectable tumors and liver cirrhosis. Nine patients received neoadjuvant chemotherapy based on the CCG-823F or CCG-8881A protocol. Two of them showed lung metastasis, but the metastatic nodules were reduced in size and number in one patient, disappeared in another patient after neoadjuvant chemotherapy. The mean tumor size at diagnosis in 9 patients was 10.5 cm (range: 6.4~14 cm). After neoadjuvant chemotherapy, the mean size reduction was 53% (range: 37~67%) in 9 patients. In 8 out of 9 patients (88%) a curative resection was performed after average 4 cycles of neoadjuvant chemotherapy. All the patients were followed for a median duration of 21 months (range: 5~88 months). Nine of all 11 patients are still alive without tumor recurrence. Conclusion: Neoadjuvant chemotherapy was able to increase the resectability of an initially unresectable hepatoblastoma and should not be abandoned even with a distant metastasis such as the lung. Liver transplantation is a good back-up for an unresectable hepatoblastoma. (J Korean Surg Soc 2002;63:337-341) KCI Citation Count: 0
Bibliography:http://kmbase.medric.or.kr/Main.aspx?d=KMBASE&m=VIEW&i=0371320020630040337
G704-000991.2002.63.4.012
ISSN:2288-6575
2288-6796